Theraclion secures AMA approval for Category III CPT code for Sonovein varicose vein HIFU procedure

• Theraclion flagged a cash runway into Q1–Q2 2027, based on €5.2 million cash at June 30, 2026.
• Runway depends on full exercise of capital-raise BSA warrants worth up to €2 million.
• Funding needs may rise if the group accelerates a US rollout tied to expected FDA De Novo timing in late Q3–early Q4 2026.
• Net proceeds of €5.8 million were received in May from an oversubscribed spring 2026 capital increase.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theraclion SA published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.